As new trials continue to improve treatment options for patients with all types of cancer, it’s “never too soon to be talking about clinical trials” with your oncologist, says Dr. Pashtoon Kasi, a clinical assistant professor of internal medicine, hematology, oncology and blood and marrow transplantation at the University of Iowa Health Care.While discussing his research into a new AI-based…
Early FDG PET/CT can identify metabolic changes in melanoma metastases that are potentially predictive of response to pembrolizumab and significantly correlated with PFS.
A phase 2 trial led by a NewYork-Presbyterian/Weill Cornell Medicine oncologist reveals the efficacy of neoadjuvant botensilimab plus balstilimab in patients with colorectal cancer.
Blood tests that detect traces of cancer cells and tumor DNA help find residual disease after treatment is completed.
Listen to this episode from The Late Night Oncology Show on Spotify. [Episódio em Inglês] Para fechar o mês de conscientização dos tumores colorretais, recebemos…
A phase 2 trial led by a NewYork-Presbyterian/Weill Cornell Medicine oncologist reveals the efficacy of neoadjuvant botensilimab plus balstilimab in patients with colorectal cancer.
Oncogene – Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
Objective We evaluated whether people who had not completed a faecal immunochemical test (FIT) for colorectal cancer (CRC) screening would complete a blood-based testing option…
Giving two immunotherapy drugs before surgery to remove colorectal cancer shows highly promising results
Reimagine Cancer Detection, Diagnosis & Patient Management through Harnessing the Potential of Liquid Biopsies
Oncogene – Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
